Compare PPG Industries, Inc. (PPG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? PPG Industries, Inc. trades at $105.43 (market cap $23.36B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.5× PPG Industries, Inc.'s market cap, and PPG Industries, Inc. pays a 2.82% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PPG | VRTX | |
|---|---|---|
Market Cap | $23.36B | $128.16B |
Volume | 1,972,399 | 806,603 |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $557.96 |
52-Week Low | $94.34 | $407.37 |
Typical Hold Time | 68 Days | 120 Days |
Enterprise Value | $29.22B | $122.29B |
Dividend Yield | 2.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG trades at $105.45, down 1.02% on the day, with a bearish technical signal from moving averages. The stock shows mixed earnings performance, missing Q4 2025 and Q2 2026 estimates but beating in Q1 2026. Fundamentals are solid with a P/E of 15.08, net income margin of 9.57%, and strong cash flow generation of $1.94B from operations in 2025. Recent news highlights margin pressures in the Automotive Refinish segment and upcoming Q3 2026 earnings on October 27.
The outlook is cautiously optimistic given analyst consensus favoring Buy with a $130 price target, implying 23% upside. Key opportunities include earnings growth and dividend stability, while risks involve segment-specific weakness and macroeconomic headwinds affecting demand. The stock's current valuation near support levels may attract value investors awaiting clearer earnings momentum.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
